We knew the CF33 is powerful itself and also crucial to the be succeeded in novel therapies CF33-CD19
and
Our management had a pre-IND meeting with FDA and received feedback and guidance back in Aug 2020
This important feedback from FDA would provide us with a clear roadmap for a successful IND submission and clinical development of CF33
Since we are in-licencing CF33 about 1.5 years ago, our management took every step seriously and carefully to make sure we will have a successful and fast pathway and now we are at the doorstep
The IND approvals will be announced soon, any days
Ann: IMUGENE LICENSES CAR T DIRECTED OV THERAPY FOR SOLID TUMOURS, page-286
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |